Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 billion. On the other hand, the company’s full-year revenue guidance of $46.75 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.58 per share was 11.1% above analysts’ consensus estimates.

Is now the time to buy BMY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed products. Management highlighted strong contributions from therapies such as Reblozyl, Breyanzi, Opdualag, Qvantig, and Cobenfy, which together delivered 9% year-over-year growth. CEO Chris Boerner credited disciplined R&D and targeted commercial efforts as central to performance, stating, “Our growth portfolio continues to strengthen our foundation for long-term growth.” The company also cited progress in cell therapy and positive developments in its regulatory pipeline as supportive factors.

Turning to the outlook for this year, Bristol-Myers Squibb’s guidance is underpinned by expectations for pivotal late-stage clinical trial readouts, lifecycle management for key products, and continued investments in R&D productivity. Management emphasized the importance of upcoming data from studies of Milvexian in atrial fibrillation and stroke prevention, as well as multiple late-stage neuroscience and immunology assets. CFO David Elkins stated, “Our strategy remains grounded in focusing R&D on life-threatening diseases, building momentum in our growth portfolio, and maintaining disciplined capital allocation.”

Key Insights from Management’s Remarks

Management attributed first quarter performance to strong execution in the growth portfolio and steady progress on pipeline milestones, while also noting product mix and inventory dynamics across the legacy business.

• Growth portfolio momentum: Expansion in newer products—particularly Reblozyl, Breyanzi, Opdualag, Qvantig, and Cobenfy—drove above-market growth, reflecting increased uptake in serious diseases and solid early lifecycle demand.
• Cell therapy strength: Breyanzi achieved 53% growth, attributed to its best-in-class profile and growing demand across approved indications in both U.S. and international markets, supporting management’s confidence in its trajectory.
• Oncology inventory headwinds: Opdivo revenues declined due to inventory drawdowns at the wholesaler level in the U.S., although management indicated this was a temporary factor and expected normalization over the rest of the year.
• Cardiovascular franchise resilience: Eliquis delivered robust growth driven by strong demand, though management noted a price reduction in the U.S. led to some inventory build, which is expected to reverse in future quarters.
• Pipeline and regulatory progress: The company achieved FDA acceptance with priority review for iberdomide in multiple myeloma and reported positive Phase III data for mozigimide and its antibody-drug conjugate programs, underscoring the breadth and diversity of its late-stage pipeline.

Drivers of Future Performance

Bristol-Myers Squibb’s forward guidance is shaped by anticipated late-stage clinical trial results, product lifecycle expansions, and ongoing productivity initiatives in R&D and operations.

• Pivotal late-stage readouts: Management pointed to upcoming data from trials of Milvexian in atrial fibrillation and stroke prevention, as well as Cobenfy in Alzheimer’s-related psychosis, as key to broadening the company’s future revenue streams and supporting portfolio diversification.
• Lifecycle and pipeline expansion: The company’s strategy includes launching more than 10 new medicines and 30 meaningful lifecycle management opportunities by the end of the decade, with a focus on targeting high unmet medical needs across oncology, cardiovascular, neuroscience, and immunology.
• Operational and R&D discipline: Management expects continued cost savings from its productivity initiative, investments in AI-driven drug development, and streamlined clinical operations to reduce cycle times, while also acknowledging the risk of generic competition and the importance of regulatory and clinical milestones for sustaining growth.

Catalysts in Upcoming Quarters

Looking ahead, our analyst team will focus on (1) the results of pivotal clinical readouts for Milvexian and Cobenfy, which are expected to shape the near-term growth trajectory; (2) regulatory milestones and approvals for pipeline assets like iberdomide and mozigimide; and (3) continued uptake and lifecycle expansion of growth portfolio products. Progress on R&D productivity and cost savings will also be key indicators for long-term execution.

Bristol-Myers Squibb currently trades at $60.25, up from $57.59 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.